{
    "nct_id": "NCT04777851",
    "official_title": "A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria",
    "inclusion_criteria": "* Signed and dated Patient Informed Consent Form (PICF)\n* ≥ 18 years-old at the time of PICF signature\n* Confirmed diagnosis of HCC\n* Intermediate-stage HCC, defined as follows:\n\n  * Multinodular HCC localized to the liver\n  * No evidence of MVI or EHS\n  * Not amenable to curative treatment\n  * Child-Pugh Class A\n  * ECOG PS 0 or 1\n  * ALBI grade 1 or 2\n* Beyond up-to-seven criteria\n* Disease amenable to TACE or TARE and no contradiction to intra-arterial treatment\n* Measurable disease by CT or MRI as per RECIST 1.1\n* No prior systemic therapy or loco-regional therapy for HCC\n* Adequate hematologic and organ function\n* Willing and able to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures\n* Women of childbearing potential (CBP) must have confirmed negative serum pregnancy test\n* Use of highly-effective contraceptive methods in women of CBP and men\n* Patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection are eligible if they meet criteria as defined within the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* No measurable tumor of a diffuse infiltrative HCC type.\n* Fibrolamellar HCC, sarcomatoid HCC or mixed hepatocellular/ cholangiocarcinoma subtypes.\n* Clinically meaningful ascites.\n* Prior treatment with regorafenib, a PD-1, PD-L1/PD-L2, or cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n* Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior to randomization.\n* Active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids.\n* Requirement of systemic treatment with either corticosteroids or other immunosuppressive medications ≤ 14 days prior to randomization.\n* Interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, or clinically significant acute lung diseases.\n* Cardiovascular conditions as defined within the protocol.\n* Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed ≤ 2 years before randomization.\n* Persistent proteinuria of NCI-CTCAE v5.0 Grade 3.\n* Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.",
    "miscellaneous_criteria": ""
}